1Zhang PP, Zhang JF, Xie HL, et al. Evaluation of glomerular filtration rate using cystatin C in diabetic pat ients analysed by multiple factors including tubular function[J]. J Int Med Res,2010,38(2) :473-483.
2Suzuki Y, Matsushita K, Seimiya M, et al. Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephrupathy in Japanese patients with type 2 diabetes [ J ]. Clin Chem Lab Med, 2012,50(10) :1833-1839.
3Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtra- tion rate from serum creatinine and cystatin C [ J]. N Engl J Med, 2012,367 ( 1 ) : 20-29.
4Chin PKL, Florkowski CM, Begg EJ. The performances of the Cock- croft-Ganh, Modification of Diet in Renal Disease Study and Chronic Kidney Disease Epidemiology Collaboration equations in predicting gentamicin clearance [ J ]. Ann Clin Biochem, 2013,50 ( 6 ) : 546 -557.
5Tent H, Waanders F, Krikken JA, et al. Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of esti- mated kidney function at population level:findings from the National FINRISK Study [ J ]. Nephrul Dial Transplant, 2012,27 ( 8 ) : 3210- 3217.
6Matsushita K, Mahmoodi BK, Woodward M. Comparison of risk predic- tion using the CKD-EPI equation and the MDRD study equation for es- timated glomerular filtration rate [ J ]. JAMA, 2012,307 ( 18 ) : 1941- 1951.
7Pavkov ME, Knowler WC, Lemley KV, et al. Early renal function de- cline in type 2 diabetes[J]. Clin J Am Soc Nephrul,2012,7( 1 ) :78- 84.
8Iliadis F, Didangelos T, Ntemka A, et al. Glomerular filtration rate esti- mation in patients with type 2 diabetes:creatinine-or cystatin C-based equations? [ J ]. Diabetologia,2011,54 ( 12 ) :2987-2994.
9Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an Early Biomarker of Nephropathy in Patients with Type 2 Diabetes[ J ]. J Korean Med Sci, 2011,26(2) :258-263.
10Hosokawa Y, Yamada Y, Obata Y, et al. Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients [ J]. Clin Exp Nephro1,2012,16 ( 3 ) :399-405.
